Browsing Tag
Progressive Pulmonary Fibrosis
2 posts
Why is Avalyn Pharma going public now, and what does it reveal about biotech risk appetite?
Avalyn Pharma has filed for a U.S. IPO to fund inhaled pulmonary fibrosis drugs. Read what the move signals for biotech markets and lung disease therapy.
Bristol Myers’ BMS-986278 yields promising results in slowing pulmonary fibrosis progression in Phase 2 trial
Bristol Myers Squibb (NYSE: BMY) disclosed a pivotal Phase 2 study highlighting that BMS-986278, an investigational oral LPA1…